Table 3. Subanalysis of responses according to patients’ characteristics.

Overall response rate (RECIST)	(%)
All evaluable patients (n=49)	51.0
Liver metastases (n=23)	52.2
No prior chemotherapy (n=16)	68.8
Prior anthracycline-based chemotherapy without taxane (n=23)	39.1
Prior anthracycline+taxane (n=5)	40.0
Prior CMF (n=5)	60.0
Prior hormone therapy (n=36)	55.6
Prior hormone therapy for MBC (n=25)	56.0
Triple-negative disease (n=9)	22.2

CMF=cyclophosphamide, methotrexate, 5-FU; MBC=metastatic breast cancer.